United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corporation submitted a Form 144 notice to sell 1,300 shares of Common Stock via a stock option exercise to be effected on 03/30/2026. The filing lists prior open-market dispositions by Christopher Causey totaling multiple transactions in January–March 2026.
United Therapeutics reported that its pivotal phase 3 TETON-1 study of nebulized Tyvaso in idiopathic pulmonary fibrosis (IPF) met its primary endpoint. Tyvaso showed superiority to placebo in preserving lung function, improving absolute forced vital capacity by 130.1 mL over 52 weeks with strong statistical significance. Integrated analyses of TETON-1 and the earlier TETON-2 study also demonstrated statistically significant benefits across the primary and most secondary endpoints, including reduced clinical worsening and fewer acute exacerbations. The company plans to submit a supplemental New Drug Application and seek priority FDA review to add IPF to Tyvaso’s labeled indications.
United Therapeutics Corp Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and, on the same date, sold 9,500 shares in a series of open-market transactions at prices around $531–$540 per share.
The filing shows this exercise-and-sell activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of up to 1,734,410 options expiring on March 17, 2027 or December 31, 2026. Following these trades, Rothblatt holds 40,513 shares of common stock directly, plus additional indirect holdings through a spouse and several family trusts.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share and acquired the related common shares.
On the same March 26, 2026, he sold a total of 10,000 common shares in multiple open‑market transactions at weighted average prices around $532–$540, pursuant to a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025. Following these transactions, he directly owned 18,876 common shares.
United Therapeutics Corp ownership update: The Vanguard Group filed Amendment No. 13 to report 0 shares beneficially owned, representing 0% of Common Stock as of 03/13/2026. The filing explains an internal realignment on 01/12/2026 that led to disaggregated reporting by Vanguard subsidiaries.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in open-market transactions on March 25, 2026. The filing shows this exercise and sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After these trades, she holds 40,513 shares directly, alongside additional indirect holdings, including 324,518 shares held by certain family trusts and 166 shares held by her spouse.
United Therapeutics director Tommy G. Thompson reported an option exercise and related share sales. He exercised stock options for 2,000 shares of common stock at $101.80 per share and received 2,000 shares on March 26, 2026. He then sold a total of 2,000 common shares in three open-market transactions at weighted average prices of $537.6192, $539.2451, and $540.1750 per share. After these transactions, he holds 8,480 common shares directly, plus indirect holdings of 8,200 shares held by a trust and 5,800 shares held by a family LLC. A footnote also notes 880 additional shares are scheduled to be issued on or about July 8, 2026 from previously vested deferred RSUs.
Tommy Thompson submitted a Rule 144 notice regarding 2,000 shares of Common Stock of the issuer. The filing lists the planned transfer as a Stock Option Exercise on 03/26/2026 for cash. The notice also records a prior sale of 2,000 shares on 03/04/2026 for $978,839.40.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options at $146.03 per share and acquired 9,500 shares of common stock on March 24, 2026. She then sold 9,500 common shares in multiple open‑market trades at prices between approximately $516.84 and $536.02, leaving 40,513 shares held directly.
The filing also lists additional indirect holdings, including shares held by her spouse and in various family trusts. A footnote states these transactions were made under a pre‑arranged 10b5‑1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at reported prices such as $518.2830, $529.0430 and $536.2750 per share. Following these transactions, he directly holds 18,876 shares of common stock. The exercise and subsequent sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.